Dr. Woodcock’s distinguished history as a career leader at the FDA will help the agency meet this challenge. Her candor and integrity have permeated her career at the agency, including through her public testimony to Congress more than 50 times under six different Administrations. Her history as an impartial civil servant will be critical in rebuilding the public’s confidence in the agency. For example, in response to concerns about contamination of the active ingredient in diabetes drugs, Dr. Woodcock called on Congress to provide funding to ensure needed oversight and inspections of overseas drug-manufacturing, earning plaudits from Congress. Former Representative John Dingell (D-Mich.), whose committee had jurisdiction over the FDA, said of Dr. Woodcock in 2008, “Again, I want it known that I appreciate Dr. Woodcock’s candor. To her credit, she has stepped forth in the midst of a public health crisis to deal honestly with Congress. How I wish others in the Administration showed the same vigor, responsiveness, and leadership.”

Dr. Woodcock’s 37 years of senior-level experience at the FDA serves as both a touchstone for how to get things done and a master class in understanding the intricacies of the agency’s work. This earned experience, and the respect that accompanies it, allow her to speak authoritatively on the processes that can be streamlined to ensure a rapid response to public health emergencies while ensuring that the structures that are vital to ensure the FDA’s mission and standards of independence and rigor are upheld. Her efforts on the “Pharmaceutical Quality for the 21st Century Initiative,” started in 2002, have helped modernize pharmaceutical manufacturing—critical regulatory issues that will be at the forefront of ensuring the production of FDA-approved vaccines and therapeutics can meet global demand. Further, her relationships and history as a civil servant will promote morale within the agency—an essential asset at a time when so much is asked of the FDA’s staff.

More broadly, Dr. Woodcock has continuously brought steadfast leadership and helped guide the agency to a patient-centered focus. Under Dr. Woodcock’s leadership from 1994-2004 and 2007-2019, the Center for Drug Evaluation and Research (CDER) regulatory decision-making processes have become more open and transparent to the public. Changes included publishing CDER’s regulatory procedures and policies; developing more than 100 technical guidance documents that describe regulatory standards; providing an unprecedented degree of participation of consumer and patient representatives in FDA processes; and creating an extensive Center web site which includes drug reviews and consumer information. Dr. Woodcock has advanced medical discoveries from the laboratory to patients more efficiently under the Critical Path Initiative; and launched the Safety First and Safe Use initiatives designed to improve drug safety management within and outside the FDA, respectively.

Senior career civil servants are required to make thousands of decisions on their careers and carefully guard their independence in a political environment. These unbiased decisions are often challenged, guided by the best available knowledge and the focus of living up to the agency’s mission. Dr. Woodcock’s principles have remained steadfast: to protect and promote the health and well-being of the American public and to base decisions on sound science in support of FDA public health mission. At the most fundamental level, Dr. Woodcock has demonstrated over nearly four decades that she cares deeply about the agency, its mission, and its people.

Our organizations enthusiastically support Dr. Woodcock’s continued service to the FDA in her role as Acting Commissioner and support her candidacy to lead the agency permanently at this critical time. We thank you for your consideration of her nomination.

Sincerely,

Dr. Woodcock's distinguished history as a career leader at the FDA will help the agency meet this challenge. Her candor and integrity have permeated her career at the agency, including through her public testimony to Congress more than 50 times under six different Administrations. Her history as an impartial civil servant will be critical in rebuilding the public’s confidence in the agency. For example, in response to concerns about contamination of the active ingredient in diabetes drugs, Dr. Woodcock called on Congress to provide funding to ensure needed oversight and inspections of overseas drug-manufacturing, earning plaudits from Congress. Former Representative John Dingell (D-Mich.), whose committee had jurisdiction over the FDA, said of Dr. Woodcock in 2008, “Again, I want it known that I appreciate Dr. Woodcock’s candor. To her credit, she has stepped forth in the midst of a public health crisis to deal honestly with Congress. How I wish others in the Administration showed the same vigor, responsiveness, and leadership.”

Dr. Woodcock’s 37 years of senior-level experience at the FDA serves as both a touchstone for how to get things done and a master class in understanding the intricacies of the agency’s work. This earned experience, and the respect that accompanies it, allow her to speak authoritatively on the processes that can be streamlined to ensure a rapid response to public health emergencies while ensuring that the structures that are vital to ensure the FDA’s mission and standards of independence and rigor are upheld. Her efforts on the “Pharmaceutical Quality for the 21st Century Initiative,” started in 2002, have helped modernize pharmaceutical manufacturing—critical regulatory issues that will be at the forefront of ensuring the production of FDA-approved vaccines and therapeutics can meet global demand. Further, her relationships and history as a civil servant will promote morale within the agency—an essential asset at a time when so much is asked of the FDA’s staff.

More broadly, Dr. Woodcock has continuously brought steadfast leadership and helped guide the agency to a patient-centered focus. Under Dr. Woodcock’s leadership from 1994-2004 and 2007-2019, the Center for Drug Evaluation and Research (CDER) regulatory decision-making processes have become more open and transparent to the public. Changes included publishing CDER’s regulatory procedures and policies; developing more than 100 technical guidance documents that describe regulatory standards; providing an unprecedented degree of participation of consumer and patient representatives in FDA processes; and creating an extensive Center web site which includes drug reviews and consumer information. Dr. Woodcock has advanced medical discoveries from the laboratory to patients more efficiently under the Critical Path Initiative; and launched the Safety First and Safe Use initiatives designed to improve drug safety management within and outside the FDA, respectively.

Senior career civil servants are required to make thousands of decisions on their careers and carefully guard their independence in a political environment. These unbiased decisions are often challenged, guided by the best available knowledge and the focus of living up to the agency’s mission. Dr. Woodcock’s principles have remained steadfast: to protect and promote the health and well-being of the American public and to base decisions on sound science in support of FDA public health mission. At the most fundamental level, Dr. Woodcock has demonstrated over nearly four decades that she cares deeply about the agency, its mission, and its people.

Our organizations enthusiastically support Dr. Woodcock’s continued service to the FDA in her role as Acting Commissioner and support her candidacy to lead the agency permanently at this critical time. We thank you for your consideration of her nomination.